
Eli Lilly (NYSE: LLY) and Boehringer Ingelheim have announced plans to conduct two outcome trials evaluating diabetes medicine Jardiance (empagliflozin) …
ESTEVE CDMO adds $17.5m to Illinois expansion
Brenntag and dsm-firmenich expand biopharma vitamin partnership

